In addition, in vivo studies using animal models of lung cancer, myelogenous leukemia and breast cancer demonstrated that deletion/inhibition of Rac resulted in significant reduction in tumor formation (Mack et al. 2011; Castillo-Pichardo et al. 2014). Here, AKT1 is linked to breast carcinoma.